RT Journal Article
SR Electronic
T1 Pretreatment Fibrinogen Level Is a Prognostic Factor for Esophageal Cancer Patients Who Receive Curative Treatment
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 249
OP 255
DO 10.21873/anticanres.16808
VO 44
IS 1
A1 AOYAMA, TORU
A1 KATO, AYA
A1 HASHIMOTO, ITARU
A1 MAEZAWA, YUKIO
A1 HARA, KENTARO
A1 KAWAHARA, SHINNOSUKE
A1 KAZAMA, KEISUKE
A1 KOMORI, KEISUKE
A1 YOSHIZAWA, SUZUE
A1 TAMAGAWA, AYAKO
A1 TATEISHI, MINORI
A1 MINAMI, TOMOYUKI
A1 CHO, HARUHIKO
A1 MORITA, JUNYA
A1 OTANI, KAZUKI
A1 SAWAZAKI, SHO
A1 NUMATA, MASAKATAU
A1 TANABE, MIE
A1 OSHIMA, TAKASHI
A1 SAITO, AYA
A1 YUKAWA, NORIO
A1 RINO, YASUSHI
YR 2024
UL http://ar.iiarjournals.org/content/44/1/249.abstract
AB Background/Aim: Pretreatment fibrinogen levels are a promising prognostic marker for some malignancies. The aim of the present study was to evaluate the clinical impact of fibrinogen levels before treatment in patients with esophageal cancer who underwent curative resection. Patients and Methods: This study included 123 patients who underwent curative treatment for esophageal cancer between 2005 and 2020. The prognosis and clinicopathological parameters in the high fibrinogen and low fibrinogen groups were analyzed. Results: Overall survival (OS) stratified by individual clinical factors was compared using the log-rank test, and a significant difference was observed when a pretreatment fibrinogen level of 400 g/dl was used as a cutoff value. The comparison of the patient background factors between the high fibrinogen (400 g/dl) and low fibrinogen (<400 g/dl) groups revealed significant differences in pathological T status and lymph node metastasis. In the low fibrinogen group, the OS rates at 3 and 5 years after surgery (71.4% and 58.1%, respectively) were significantly higher than those in the high fibrinogen group (38.3% and 32.4%, respectively). Univariate and multivariate analyses for OS showed that the fibrinogen level prior to treatment was a significant prognostic factor. Similar results were observed for recurrence-free survival. In addition, when the first recurrence site was compared, there were marginally significant differences in hematologic recurrence. Conclusion: Pretreatment fibrinogen levels are a significant risk factor in patients with esophageal cancer. Therefore, pretreatment fibrinogen levels are a promising prognostic factor for patients with esophageal cancer.